Lupin Ltd Receives EIR from US FDA for its Goa Facility with Satisfactory VAI Classification

Global pharma major Lupin Limited has announced that it has received the Establishment Inspection Report (EIR) from the United States Food and Drug Administration (US FDA) for its facility in Goa, India. The EIR was issued following an inspection of the facility from November 10 to November 21, 2025, and it has been classified as Voluntary Action Indicated (VAI). This outcome reflects Lupin's continued focus on quality excellence and regulatory compliance, reinforcing its commitment to delivering safe and effective medicines to patients worldwide.